Program
Ranibizumab
Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.
Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 560 open or running | phase 4since Jul 19, 2007 | Jan 11, 2006 | none ahead |
| Hoffmann-La Rocheits history only | 244 open or running | phase 4since Jan 13, 2011 | Mar 24, 2003 | Feb 4, 2027phase 3 · NCT04657289 |
| AbbVieits history only | 31 open or running | phase 4since Aug 31, 2011 | Oct 16, 2008 | Jul 2031phase 2 · NCT05210803 |
| Samsung Bioepisits history only | 20 open or running | phase 2since Dec 11, 2023 | Dec 11, 2023 | none ahead |
| Santen Pharmaceuticalits history only | 20 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| AO GENERIUMits history only | 11 open or running | phase 3since Nov 30, 2020 | Nov 30, 2020 | none ahead |
| bioeq-gmbhits history only | 10 open or running | phase 3since Nov 19, 2015 | Nov 19, 2015 | none ahead |
| Cynosure Lutronicits history only | 10 open or running | phase 4since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Formyconits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Mar 5, 2024 | Mar 5, 2024 | none ahead |
| oraya-therapeutics-incits history only | 10 open or running | no phasesince Jan 24, 2012 | Jan 24, 2012 | none ahead |
| pfenex-incits history only | 10 open or running | phase 2since Apr 17, 2014 | Apr 17, 2014 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| qlt-incits history only | 10 open or running | phase 2since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| shanghai-biomabs-pharmaceutical-co-ltdits history only | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
| xbrane-biopharma-abits history only | 10 open or running | phase 3since Jan 8, 2019 | Jan 8, 2019 | none ahead |
Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Mar 11, 2011.
- Aug 5, 2020Phase 3 study in Diabetic RetinopathyHoffmann-La Roche · NCT04503551 · 174 enrolled · United States, Puerto Rico
- Sep 24, 2020Phase 2 study in Macular DegenerationHoffmann-La Roche · NCT04567303 · 177 enrolled · United States, Puerto Rico
- Nov 30, 2020AO GENERIUM’s first study: phase 3 study in Macular DegenerationNew to AO GENERIUMAO GENERIUM · NCT04667039 · 408 planned · Russian Federation
- Dec 1, 2020Phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)Hoffmann-La Roche · NCT04657289 · 451 enrolled · Argentina, Australia, Austria and more
- Apr 16, 2021Phase 4 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT04853251 · 188 enrolled · United States
- May 6, 2021shanghai-biomabs-pharmaceutical-co-ltd’s first study: phase 1 study in Wet Age-related Macular DegenerationNew to shanghai-biomabs-pharmaceutical-co-ltdshanghai-biomabs-pharmaceutical-co-ltd · NCT04884399 · 24 enrolled · China
- Oct 28, 2021Phase 3 study in Neovascular Age-Related Macular DegenerationHoffmann-La Roche · NCT05126966 · Argentina, Denmark, Greece and more
- Jan 14, 2022Phase 2 study in Neovascular Age-Related Macular Degeneration (nAMD)AbbVie · NCT05210803 · 116 planned · United States
- Sep 15, 2022Phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT05562947 · 68 enrolled · China
- Dec 11, 2023Samsung Bioepis’s first study: phase 2 study in Macular EdemaNew to Samsung BioepisSamsung Bioepis · NCT06176963 · 34 enrolled · Poland
- Mar 5, 2024Incepta Pharmaceuticals’ first study: phase 3 study in Diabetic RetinopathyNew to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT06305416 · 70 enrolled · Bangladesh
- Nov 25, 2024Formycon’s first study: phase 4 study in Macular DegenerationNew to FormyconFormycon · NCT06708624 · 31 enrolled · United States
- Feb 21, 2025Phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT06847542 · 250 planned · Austria, Czechia, Denmark and more
- Apr 19, 2026Phase 2 study in Macular DegenerationSamsung Bioepis · NCT07550504 · 30 enrolled · Poland
Ahead
- Feb 4, 2027Primary completion: phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)Hoffmann-La Roche · NCT04657289
- Jun 30, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT05562947
- Jul 30, 2027Primary completion: phase 4 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT04853251
- Nov 15, 2028Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT06847542
TargetBeta
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
The newest 60 of 98 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07550504Macular Degeneration · Poland | 2 | Completed | Samsung Bioepis | Mar 31, 2026 | 30 |
| NCT06847542Neovascular Age-related Macular Degeneration · Austria, Czechia, Denmark and more | 3 | Recruiting | Hoffmann-La Roche | Nov 15, 2028 | 250 |
| NCT06708624Macular Degeneration · United States | 4 | Completed | Formycon | Aug 8, 2024 | 31 |
| NCT06305416Diabetic Retinopathy · Bangladesh | 3 | Completed | Incepta Pharmaceuticals | Mar 10, 2026 | 70 |
| NCT06176963Macular Edema · Poland | 2 | Completed | Samsung Bioepis | Nov 30, 2023 | 34 |
| NCT05562947Neovascular Age-related Macular Degeneration · China | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 68 |
| NCT05210803Neovascular Age-Related Macular Degeneration (nAMD) · United States | 2 | By invitation | AbbVie | Jul 2031 | 116 |
| NCT05126966Neovascular Age-Related Macular Degeneration · Argentina, Denmark, Greece and more | 3 | Withdrawn | Hoffmann-La Roche | Jan 31, 2025 | 0 |
| NCT04884399Wet Age-related Macular Degeneration · China | 1 | Completed | shanghai-biomabs-pharmaceutical-co-ltd | Dec 22, 2022 | 24 |
| NCT04853251Neovascular Age-related Macular Degeneration · United States | 4 | Active, not recruiting | Hoffmann-La Roche | Jul 30, 2027 | 188 |
| NCT04657289Neovascular Age-related Macular Degeneration (nAMD) · Argentina, Australia, Austria and more | 3 | Active, not recruiting | Hoffmann-La Roche | Feb 4, 2027 | 451 |
| NCT04667039Macular Degeneration · Russian Federation | 3 | Recruiting | AO GENERIUM | Aug 15, 2024 | 408 |
| NCT04567303Macular Degeneration · United States, Puerto Rico | 2 | Completed | Hoffmann-La Roche | Aug 25, 2026 | 177 |
| NCT04503551Diabetic Retinopathy · United States, Puerto Rico | 3 | Completed | Hoffmann-La Roche | Oct 3, 2022 | 174 |
| NCT03927690Macular Degeneration · United States, Germany, Puerto Rico and more | 2 | Completed | Novartis | Jun 17, 2022 | 91 |
| NCT03805100Macular Degeneration · United States, Bulgaria, Czechia and more | 3 | Completed | xbrane-biopharma-ab | May 11, 2021 | 582 |
| NCT03759860Diabetic Macular Edema · Korea, Republic of | 4 | UNKNOWN | Cynosure Lutronic | Jul 30, 2019 | 12 |
| NCT03312283Wet Age-related Macular Degeneration · China | 1 | Completed | Qilu Pharmaceutical | Apr 2, 2019 | 48 |
| NCT03211234Macular Degeneration · United States, Philippines | 2 | Completed | Santen Pharmaceutical | Dec 31, 2019 | 76 |
| NCT02878681Visual Impairment Due to Diabetic Macular Edema | 4 | Withdrawn | Novartis | Sep 2017 | 0 |
| NCT02698566Macular Edema · United States | 3 | Completed | Hoffmann-La Roche | Apr 5, 2016 | 35 |
| NCT02634970Neovascularization, Pathologic | 4 | Withdrawn | Novartis | Dec 2017 | 0 |
| NCT02640664Retinopathy of Prematurity · United States, Austria, Belgium and more | 3 | Completed | Novartis | Apr 21, 2022 | 180 |
| NCT02611778Macular Degeneration · Austria, Czechia, France and more | 3 | Completed | bioeq-gmbh | Dec 2017 | 712 |
| NCT02577107Macular Degeneration · China | 4 | Completed | Novartis | Jul 9, 2016 | 12 |
| NCT02510794Macular Degeneration · United States | 2 | Completed | Hoffmann-La Roche | Apr 10, 2018 | 225 |
| NCT02484690Choroidal Neovascularization · United States | 2 | Completed | Hoffmann-La Roche | Sep 26, 2017 | 273 |
| NCT02375971Retinopathy of Prematurity · United States, Austria, Belgium and more | 3 | Completed | Novartis | Dec 14, 2017 | 224 |
| NCT02366468Diabetic Retinopathy · Germany | 4 | Completed | Novartis | Jun 8, 2017 | 135 |
| NCT02259088Vision Disorders · China | 3 | Completed | Novartis | Jan 17, 2017 | 384 |
| NCT02258009Visual Impairment Due to Diabetic Macular Edema · Germany | 4 | Withdrawn | Novartis | Oct 2016 | 0 |
| NCT02257632Wet Age-Related Macular Degeneration · Germany | 4 | Completed | Novartis | Mar 20, 2017 | 41 |
| NCT02161575Macular Degeneration · Germany, United Kingdom | 4 | Completed | Novartis | Sep 14, 2017 | 103 |
| NCT02121353Macular Degeneration · New Zealand | 2 | Completed | pfenex-inc | Jan 2016 | 25 |
| NCT02130024Macular Degeneration · Australia | 4 | Completed | Novartis | Nov 15, 2017 | 281 |
| NCT02034006Myopia, Degenerative · Italy | 3 | Completed | Novartis | Jul 15, 2016 | 200 |
| NCT02032173Macular Edema · France | 3 | Terminated | Novartis | Apr 29, 2015 | 31 |
| NCT01986907Macular Degeneration · Italy | 4 | Completed | Novartis | Jun 15, 2016 | 1,049 |
| NCT01972789Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD · Australia | 4 | Completed | Novartis | Feb 28, 2017 | 349 |
| NCT01976338Macular Edema · China, Hong Kong, Indonesia and more | 3 | Completed | Novartis | Mar 28, 2016 | 283 |
| NCT01976312Retinal Vein Occlusion · China, Hong Kong, India and more | 3 | Completed | Novartis | Mar 14, 2016 | 252 |
| NCT01958918Neovascular Age-related Macular Degeneration · Austria, Belgium, Denmark and more | 4 | Completed | Novartis | Nov 22, 2016 | 712 |
| NCT01948830Macular Degeneration · Belgium, Chile, Croatia and more | 3 | Completed | Novartis | Nov 19, 2015 | 650 |
| NCT01922102Choroidal Neovascularization · China, Hong Kong, India and more | 3 | Completed | Novartis | Sep 14, 2016 | 457 |
| NCT01908816Choroidal Neovascularization · France | 3 | Completed | Novartis | Jan 8, 2016 | 270 |
| NCT01846299Macular Edema · Australia, Belgium, Canada and more | 3 | Completed | Novartis | Sep 2015 | 181 |
| NCT01840410Choroidal Neovascularization · Australia, Canada, Czech Republic and more | 3 | Completed | Novartis | Nov 2015 | 183 |
| NCT01780935Neovascular Age-related Macular Degeneration · Argentina, Austria, Canada and more | 3 | Completed | Novartis | Jul 9, 2015 | 671 |
| NCT01775124Macular Degeneration · China | 4 | Completed | Novartis | Nov 23, 2015 | 332 |
| NCT01594281Proliferative Diabetic Retinopathy (PDR) · Germany | 2 | Completed | Novartis | Nov 30, 2016 | 107 |
| NCT01599650Retinal Vein Occlusion · Australia, Canada, Czech Republic and more | 3 | Completed | Novartis | May 2015 | 455 |
| NCT01580020Retinal Vein Occlusion · Germany | 4 | Completed | Novartis | Oct 2014 | 175 |
| NCT01535261Macular Edema · Australia, Austria, Canada and more | 3 | Completed | Novartis | Mar 2015 | 357 |
| NCT01521819Macular Degeneration · Italy | – | UNKNOWN | oraya-therapeutics-inc | Aug 2013 | 12 |
| NCT01442064Macular Edema | – | Completed | Hoffmann-La Roche | Jul 2010 | 608 |
| NCT01427751Retinal Vein Occlusion · France, Germany, Israel and more | 4 | Completed | AbbVie | Nov 4, 2014 | 307 |
| NCT01396083Vision Disorders · Germany, Hungary, Poland and more | 3 | Completed | Novartis | Jan 2014 | 243 |
| NCT01396057Vision Disorders · Czech Republic, Germany, Hungary and more | 3 | Completed | Novartis | Jun 2013 | 244 |
| NCT01377597Retinal Vein Occlusion · Japan | 3 | Completed | Novartis | Apr 2012 | 47 |
| NCT01315275Vision Disorders · France | 4 | Completed | Novartis | Aug 2012 | 394 |
How it is read
Names in the registry
- “Ranibizumab”, 40 entries
- “ranibizumab”, 18 entries
- “Ranibizumab 0.5 mg”, 11 entries
- “rhuFab V2 (ranibizumab)”, 6 entries
- “Ranibizumab 0.5mg”, 4 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 41 studies
- Macular Edema, 22 studies
- Choroidal Neovascularization, 15 studies
- Retinal Vein Occlusion, 7 studies
- Vision Disorders, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.